TY - JOUR
T1 - Triple-negative breast cancer histological subtypes with a favourable prognosis
AU - Cserni, Gábor
AU - Quinn, Cecily M.
AU - Foschini, Maria Pia
AU - Bianchi, Simonetta
AU - Callagy, Grace
AU - Chmielik, Ewa
AU - Decker, Thomas
AU - Fend, Falko
AU - Kovács, Anikó
AU - van Diest, Paul J.
AU - Ellis, Ian O.
AU - Rakha, Emad
AU - Tot, Tibor
N1 - Funding Information:
John House, Premier Inc.; Yulia Carroll, Melissa Danielson, Hussain Yusuf; members of the CDC COVID-19 Response Data, Analytics, and Modeling Task Force.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Triple-negative breast cancers (TNBC), as a group of tumours, have a worse prognosis than stage-matched non-TNBC and lack the benefits of routinely available targeted therapy. However, TNBC is a heterogeneous group of neoplasms, which includes some special type carcinomas with a relatively indolent course. This review on behalf of the European Working Group for Breast Screening Pathology reviews the literature on the special histological types of BC that are reported to have a triple negative phenotype and indolent behaviour. These include adenoid cystic carcinoma of classical type, low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, low-grade mucoepidermoid carcinoma, secretory carcinoma, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. The pathological and known molecular features as well as clinical data including treatment and prognosis of these special TNBC subtypes are summarised and it is concluded that many patients with these rare TNBC pure subtypes are unlikely to benefit from systemic chemotherapy. A consensus statement of the working group relating to the multidisciplinary approach and treatment of these rare tumour types concludes the review.
AB - Triple-negative breast cancers (TNBC), as a group of tumours, have a worse prognosis than stage-matched non-TNBC and lack the benefits of routinely available targeted therapy. However, TNBC is a heterogeneous group of neoplasms, which includes some special type carcinomas with a relatively indolent course. This review on behalf of the European Working Group for Breast Screening Pathology reviews the literature on the special histological types of BC that are reported to have a triple negative phenotype and indolent behaviour. These include adenoid cystic carcinoma of classical type, low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, low-grade mucoepidermoid carcinoma, secretory carcinoma, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. The pathological and known molecular features as well as clinical data including treatment and prognosis of these special TNBC subtypes are summarised and it is concluded that many patients with these rare TNBC pure subtypes are unlikely to benefit from systemic chemotherapy. A consensus statement of the working group relating to the multidisciplinary approach and treatment of these rare tumour types concludes the review.
KW - Acinic cell carcinoma
KW - Adenoid cystic carcinoma
KW - Fibromatosis like metaplastic carcinoma
KW - Low-grade adenosquamous carcinoma
KW - Mucoepidermoid carcinoma
KW - Secretory carcinoma
KW - Tall cell carcinoma with reversed polarity
KW - Triple negative breast cancer
UR - https://www.scopus.com/pages/publications/85118873460
U2 - 10.3390/cancers13225694
DO - 10.3390/cancers13225694
M3 - Review article
AN - SCOPUS:85118873460
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 22
M1 - 5694
ER -